Search research articles
Contact Us
Filters
Showing results (31-40 of 33) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 33 results.
Breast Cancer Research and Treatment
|
January 5, 2022
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort
M Bringuier, M Carton, C Levy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 18, 2020
Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016
Matthieu Frasca, Camille Sabathe, Suzette Delaloge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
J-Y Pierga, F-C Bidard, A Autret, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 33) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 33 results.
Breast Cancer Research and Treatment
|
January 5, 2022
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort
M Bringuier, M Carton, C Levy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 18, 2020
Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016
Matthieu Frasca, Camille Sabathe, Suzette Delaloge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
J-Y Pierga, F-C Bidard, A Autret, et al.
Page
of 4